Interest is growing in discussions by the Ministry of Health, Labor and Welfare’s (MHLW) new expert panel on comprehensive pharmaceutical measures. At its meeting on September 22, major trade groups made their cases to push for a re-think of the…
HOME > ORGANIZATION
ORGANIZATION
- JMA Vice Pres. Nakagawa Urges Pharmacies to Rigidly Check Medical Exam History of Epadel OTC Buyers
January 15, 2013
- JMA Sets Up “Council on Medical COI” Out of Concerns Over Transparency GL
January 11, 2013
- JPWA Chief Bessho Calls for Clearer Rule for Sales Tax on Ethical Drugs
January 10, 2013
- Efforts to Promote Generic Substitution Preferable to Cutting Prices of Long-Listed Drugs: Mr Sawai of JGA
January 8, 2013
- Member Companies to Begin Enforcing New COP in FY2013: JPMA President Teshirogi
January 7, 2013
- JPMA to Ask Abe Administration to Continue Former Dialogue with Pharmaceutical Industry: Dr Teshirogi
January 7, 2013
- NHO to Review Calculation Method for Clinical Trial Costs
December 28, 2012
- JPA to Hold Workshops to Train Pharmacists to Make Clinical Assessments Based on Subjective Symptoms
December 26, 2012
- JMA to Discuss JPMA’s Transparency Guidelines with JPMA, Related Medical Organizations
December 25, 2012
- “New Administration Needed to Allocate Personnel to Cabinet, LDP to Work Out Challenges”: Keizai Doyukai Chair Hasegawa
December 19, 2012
- Generic Market Share at 25.4% in 2nd Quarter on Volume Basis: JGA
December 14, 2012
- Tohoku Pharmaceutical Univ. to Acquire Tohoku Kosei Nenkin Hospital, Aiming to Turn It into Model Hospital for Pharmaceutical Education
December 14, 2012
- Panelists at IGPA Conference Express Concern that FTA Could Strengthen Intellectual Property Rights
December 10, 2012
- GIST Patients Group Submits Petition Calling for Early Filing for Regorafenib for GIST
December 10, 2012
- Kyoto Declaration Calls for Strict Quality Control of Generics: IGPA Annual Conference
December 10, 2012
- Biosimilars Popular Topic at IGPA Annual Conference
December 10, 2012
- Ways to Deal with Biosimilars Will Be Common Challenge Among Generics Companies: JGA President Sawai
December 6, 2012
- Drug Costs Should Be Basically Borne by Patients under Compassionate Use System: JPMA’s Kuwahara
December 5, 2012
- 80 Medical Institutions Submit Comprehensive Agreements on Info Disclosure in Response to JPMA Transparency GLs
December 4, 2012
- Top Officials of FPMAJ, JGA Disagree on Progress in Generic Drug Use at CSIMC Expert Subcommittee Meeting
November 30, 2012
ページ
Healthcare in the US is a highly political topic, with one end of the political spectrum arguing for broader government-sponsored access and the other advocating for more of a free-market approach. While the US market has typically been the primary…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…